AFib ablation slashed progression risk; FDA panel pans empagliflozin for type 1 diabetes
Summary: AFib ablation slashed progression risk; FDA panel pans empagliflozin for type 1 diabetes
Summary: AFib ablation slashed progression risk; FDA panel pans empagliflozin for type 1 diabetes